logo
logo

Virtue Diagnostics Closes $100 Million Series B Funding

Jan 06, 2022•over 3 years ago

Amount Raised

$100 Million

Round Type

series b

ShanghaiAppsHealth Care

Description

Virtue Diagnostics, an innovative IVD company, has just announced closing US$100 million in Series B funding. Virtue Diagnostics, founded in 2019, is focused on clinical tests for China and emerging markets. Sequoia China and Morningside Ventures jointly led the investment round with ORIZA Holdings. Existing investors Lilly Asia Ventures and PerkinElmer Ventures participated while HAOYUE Capital was the exclusive financial advisor.

Company Information

Company

Virtue Diagnostics

Location

Shanghai, Shanghai, China

About

Virtue Diagnostics is an innovative IVD company focused on infectious disease, cancer, and chronic diseases.Our goal is to utilize our diverse technology platforms to provide clinical solutions for patients at all disease stages including early screening, initial diagnosis, treatment monitoring and minimal residual disease management.www.Virtuedx.com

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech